Transgenically produced antithrombin III
AssigneeGTC Biotherapeutics, Inc.
InventorsPaul DiTullio, Harry M. Meade, Edward S. Cole
Life of this patent
Estimating the term…
Abstract
This invention relates to transgenically produced human Antithrombin III (tgATIII). The human ATIII produced by the transgenic process of the present invention has a monosaccharide composition which comprises N-acetylgalactosamine (GalNAc) along with fucose, N-acetylglucosamine, galactose, mannose, and N-acetylneuraminic acid/N-glycolyneuraminic acid. The monosaccharide composition differs with that of plasma derived ATIII (phATIII). It has been found that tgATIII has an increased clearance rate when compared to phATIII.
Claims5
A method of treating a subject having an antithrombin III (ATIII) deficiency or inflammation, comprising:
- administering to the subject a non-human mammal mammary gland produced recombinant antithrombin III (ATIII).
Dependencies are inferred from the claim text.